CDTX Valuation
Cidara Therapeutics Inc
$
21.900
- Overview
- Forecast
- Valuation
CDTX Relative Valuation
CDTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CDTX is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.47
P/B
Median3y
0.68
Median5y
1.25
-77.97
FCF Yield
Median3y
-68.28
Median5y
-55.43
Competitors Valuation Multiple
The average P/S ratio for CDTX's competitors is 8.29, providing a benchmark for relative valuation. Cidara Therapeutics Inc Corp (CDTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
SMLR
Semler Scientific Inc
34.280
USD
+3.00%
GNK
Genco Shipping & Trading Ltd
12.700
USD
+3.59%
VEL
Velocity Financial Inc
17.620
USD
+0.28%
CAPR
Capricor Therapeutics Inc
13.150
USD
-5.33%
ODC
Oil-Dri Corporation of America
41.890
USD
-0.07%
INV
Innventure Inc
4.300
USD
-1.60%
AUNA
Auna SA
6.910
USD
-0.86%
TRST
TrustCo Bank Corp NY
30.400
USD
+1.88%
IMNM
Immunome Inc
8.500
USD
+3.79%
EU
enCore Energy Corp
1.420
USD
+9.23%
FAQ
Is Cidara Therapeutics Inc (CDTX) currently overvalued or undervalued?
Cidara Therapeutics Inc (CDTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 60.38. The fair price of Cidara Therapeutics Inc (CDTX) is between to according to relative valuation methord.
What is Cidara Therapeutics Inc (CDTX) fair value?
How does CDTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Cidara Therapeutics Inc (CDTX) as of Apr 24 2025?
What is the current FCF Yield for Cidara Therapeutics Inc (CDTX) as of Apr 24 2025?
What is the current Forward P/E ratio for Cidara Therapeutics Inc (CDTX) as of Apr 24 2025?